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Abstract: A small of population of slow cycling and chemo-resistant cells referred to as cancer stem
cells (CSC) have been implicated in cancer recurrence. There is emerging interest in developing
targeted therapeutics to eradicate CSCs. Aldehyde-dehydrogenase (ALDH) activity was shown to
be a functional marker of CSCs in ovarian cancer (OC). ALDH activity is increased in cells grown
as spheres versus monolayer cultures under differentiating conditions and in OC cells after treatment
with platinum. Here, we describe the activity of CM37, a newly identified small molecule with
inhibitory activity against ALDH1A1, in OC models enriched in CSCs. Treatment with CM37 reduced
OC cells’ proliferation as spheroids under low attachment growth conditions and the expression of
stemness-associated markers (OCT4 and SOX2) in ALDH+ cells fluorescence-activated cell sorting
(FACS)-sorted from cell lines and malignant OC ascites. Likewise, siRNA-mediated ALDH1A1
knockdown reduced OC cells’ proliferation as spheres, expression of stemness markers, and delayed
tumor initiation capacity in vivo. Treatment with CM37 promoted DNA damage in OC cells,
as evidenced by induction of γH2AX. This corresponded to increased expression of genes involved
in DNA damage response, such as NEIL3, as measured in ALDH+ cells treated with CM37 or in
cells where ALDH1A1 was knocked down. By inhibiting ALDH1A1, CM37 augmented intracellular
ROS accumulation, which in turn led to increased DNA damage and reduced OC cell viability.
Cumulatively, our findings demonstrate that a novel ALDH1A1 small molecule inhibitor is active
in OC models enriched in CSCs. Further optimization of this new class of small molecules could
provide a novel strategy for targeting treatment-resistant OC.
Keywords: ovarian cancer; ALDH1A1; CM37; cancer stem cells
1. Introduction
Ovarian cancer (OC) has the highest fatality rate of any gynecologic cancer [1]. Although OC is
considered a chemo-responsive tumor with very high initial response rates to standard platinum-based
therapy [2], most women eventually develop recurrence, which rapidly evolves into resistant disease
and is incurable [2]. One of the critical factors contributing to relapse is persistence of quiescent cancer
cells that are not eliminated by chemotherapy. It has been speculated that these residual cells are cancer
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stem cells (CSCs), which can subsequently differentiate and generate recurrent tumors. CSCs have been
isolated from OC cell lines, malignant ascites, and primary tumors [3–5]. CSCs are characterized by
the expression of specific cell surface markers and the ability to self-renew, differentiate, and generate
tumors when injected in small numbers into NOD/SCID mice. In culture, CSCs grow as spheres,
are able to differentiate into cell subtypes with different phenotypes, and have been implicated in tumor
heterogeneity, tumor dormancy, and resistance to chemotherapy and radiation [6]. Several surface
markers have been proposed for ovarian CSC identification, including CD44+/CD117+, CD44+/MyoD,
CD133+, CD133/ALDH+, or ALDH+. CD44/CD117+ cells are resistant to chemotherapy, generate
tumors in immunodeficient mice and display activation of recognized stem cell pathways (e.g., nanog,
nestin, notch) [5]. CD44+/MyoD+ cells generate tumors, grow as spheroids and are highly resistant to
chemotherapy [7]. CD133+ cells are highly resistant to platinum [8], while ALDH+ cells are tumorigenic
in vivo, express stem cell restricted transcription factors, form spheres in non-adherent cultures,
and are chemoresistant [4,9,10]. Double positive ALDH+/CD133+ cells are highly tumorigenic
and chemo-resistant and represent a rare cell subpopulation within tumors [4]. Here, we focused on
the properties of ALDH+ cells and new modalities to target them.
The highly conserved aldehyde dehydrogenase (ALDH) family includes 19 enzymes involved
in the metabolism of reactive aldehydes [11]. Through their detoxification functions, ALDHs exert
cytoprotective roles in various tissues [12]. In addition, the enzymes catalyze retinol oxidation to
retinal, a limiting step during the synthesis of retinoic acid, which activates an important cellular
differentiation pathway. Recent reports have linked ALDHs, and particularly ALDH1A1, to stem cells,
both in normal tissues, such as the hematopoietic milieu [13], as well as in malignancy [14]. It remains
unknown whether the enzyme is only a marker for stem cells or whether it is functionally implicated
in maintaining their characteristics. While several other markers have been proposed over the years
for identifying ovarian CSCs [5], ALDH1A1 activity detectable through the Aldefluor assay has been
validated by several groups, and appears to be a robust phenotype [4,10,15]. The percentage of ALDH+
cells in high grade serous ovarian cancer (HGSOC) cell lines varies between 0.2% to 10%, and ALDH
expression is higher in mucinous and endometrioid cancers compared to serous carcinomas [16].
Furthermore, ALDH positivity in OC has been correlated with worse patient survival [16,17].
An enrichment in ALDH+ cells was observed after treatment with platinum both in cells lines
and xenografts [18,19], supporting the hypothesis that post-therapy tumors are enriched in cells
with progenitor characteristics.
In recent years, emerging efforts have focused on developing new therapies targeting CSCs [20].
Various strategies have been pursued, including agents which block pathways selectively activated
in stem cells [21] or which target specific markers expressed on the surface of CSCs. As high ALDH
activity appears to be a hallmark of ovarian CSCs [22], development of inhibitors for this family of
enzymes is garnering interest [23,24]. We have previously reported that CM37, a small molecule
inhibitor for ALDH1A1 discovered from a high-throughput screen of a diverse chemical library,
was a potent inhibitor of OC cell proliferation as spheres but had modest effects on differentiated
cells [25]. Here, we describe in further detail the effects of this selective inhibitor in ovarian cancer
models and the significance of the ALDH1A1 enzyme to the ovarian cancer stemness phenotype.
2. Results
2.1. CM37 Reduces ALDH Activity and Cell Proliferation in OC Cells
CM37 is a small molecule with a molecular weight of 431.6 Daltons, good predicted drug
properties, and no structural similarity to any other aldehyde dehydrogenase inhibitors [26].
The structure of CM37 is shown in Figure 1A. CM37 is a selective and competitive inhibitor of
ALDH1A1 with a Ki of 300 nM [25]. The drug has minimal inhibitory effects for ALDH1A2,
ALDH1A3, ALDH2, or ALDH3A1 at concentrations up to 20 µM [25] (Figure 1B). To investigate
its effects on spheroid formation and proliferation, we measured cell viability in FACS-sorted ALDH+
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patient-derived OC cells treated with increasing doses of CM37 or control (Figure 1C). A colorimetric
CCK8 assay revealed that CM37 significantly reduced the number of live cells in spheroids at all doses
(p < 0.0001, Figure 1D). To measure its inhibitory activity for ALDH, flow cytometry analyzed Aldefluor
enzymatic activity in CM37-treated malignant ascites-derived cells. While 19.2% of vehicle-treated
cells displayed high ALDH activity, CM37-treated primary OC cells displayed reduced percentages
of ALDH+ cells: 7.6%, 10.4%, 8.2%, and 4.9% after treatment with 100 nM, 500 nM, 1 µM, and 5 µM
CM37, respectively (Figure 1E). These results were recapitulated in the HGSOC cell line, OVCAR5.
While 8.4% of DMSO-treated OVCAR5 cells exhibited high ALDH activity, a dose-dependent decrease
in the ALDH+ population was observed after treatment with CM37 (Figure 1F). A colorimetric CCK8
assay demonstrated that cell proliferation as spheres was significantly blocked by the ALDH inhibitor;
starting at the concentration of 1 µM (p < 0.001, Figure 1G). Furthermore, the expression of markers
associated with stem cell phenotype was tested in ALDH+ OVCAR5 cells treated with 1 µM CM37
for 24 h. CM37 treatment caused a 5- (p = 0.002) and 2-fold (p = 0.03) decrease in KLF4 and NANOG
mRNA expression levels, respectively, while CDKN1A/p21, OCT4, and SOX2 mRNA levels were
undetectable in CM37-treated cells compared to control treated cells (Figure 1H).
The effects of CM37 on OC cell proliferation cultured as spheres were confirmed in other
representative HGSOC cell lines, such as OVCAR8 and OVCAR3. At concentrations ranging from 5
to 20 µM, CM37 significantly blocked sphere formation and ATP production measuring live cells in
spheroids derived from OVCAR8 cells (p < 0.001; Figure 2A,B). While sphere disruption induced
by CM37 was observed by phase contrast microscopy in OVCAR3 cells at concentrations ≥5 µM
(Figure 2C), ATP production measuring live cells was decreased only at 20 µM concentration of CM37
(p < 0.0001; Figure 2D).
Given the observed differences in sensitivity to CM37 between the tested OC cell lines
and the known selectivity of CM37 to ALDH1A1, which is hypothesized to play a key role defining
ovarian cancer stemness, we measured the relative abundance of ALDH1 isoforms in the main cell
lines utilized in this study. We observed that ALDH1A1 was the predominantly expressed isoform in
OVCAR3 and SKOV3 cells (Figure 2E,F), ALDH1A1 and ALDH1A3 were abundantly expressed in
OVCAR5, and ALDH1A2 was predominant in COV362 cells (Figure 2G,H).
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Figure 1. Effects of CM37 on ovarian cancer (OC) sphere formation and stemness markers. (A) The 
chemical structure of CM37; (B) percent inhibition of aldehyde-dehydrogenase (ALDH) enzymatic 
activity by 20 µM CM37 measured in vitro for the different orthologues; (C) spheres derived from 
primary OC cells isolated from ascites fluid and treated with control or increasing doses of CM37 
were photographed with an inverted microscope at 100× magnification. (D) Numbers of live cells 
growing as spheres were assessed by CCK-8 colorimetric assay in patient-derived OC cells. (E) 
Percentage of ALDH+ cells in untreated/or CM37-treated (500 nM–5 µM) patient-derived OC cells. 
(F) Percentage of ALDH+ cells in untreated/or CM37-treated (2.5–10 µM) OVCAR5 cells. (G) OVCAR5 
cells were plated under low attachment conditions for six days; numbers of live cells were assessed 
by using the CCK8 colorimetric assay. (H) Relative expression of stem cell markers KLF4, Nanog, Oct4, 
Sox2 as measured by qRT-PCR in ALDH+ FACS-sorted OVCAR5 cells treated with CM37 (1 µM) for 
24 h. Bars represent averages of triplicate measurements; **** corresponds to p < 0.0001; *** 
corresponds to p < 0.001. 
i r . Effects of CM37 on ovari cancer (OC) sphere f rmation and stemness markers.
(A) The chemical structure of CM37; (B) percent inhibition of aldehyde-dehydrogenas (ALDH)
enzymatic activity by 20 µM CM37 measured in vitro for the different orthologues; (C) spheres derived
fro primary OC cells isolated from ascites fluid and treated with control or increasing doses of
CM37 were photographed with an inverted microscope at 100× magnification. (D) Numbers of
live cells growing as spheres were assessed by CCK-8 colorimetric assay in patient-derived OC
cells. (E) Percentage of ALDH+ cells in untreated/or CM37-treated (500 nM–5 µM) patient-derived
OC cells. (F) Percentage of ALDH+ cells in untreated/or CM37-treated (2.5–10 µM) OVCAR5 cells.
(G) OVCAR5 cells were plated under low attachment conditions for six days; numbers of live cells
were assessed by using the CCK8 colorimetric assay. (H) Relative expression of stem cell markers KLF4,
Nanog, Oct4, Sox2 as measured by qRT-PCR in ALDH+ FACS-sorted OVCAR5 cells treated with CM37
(1 µM) for 24 h. Bars represent averages of triplicate measurements; **** corresponds to p < 0.0001;
*** corresponds to p < 0.001.
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Figure 2. Effects of CM37 on OC sphere formation: CM37 disrupts ALDH1A1-mediated sphere 
formation and growth under low attachment conditions. (A,B) OVCAR8 cells were treated with 
DMSO or 1–20 µM CM37 for six days, and numbers of live cells were assessed by quantifying ATP 
production via Cell-Titer Glo assay. Spheres were photographed with an inverted microscope at 100× 
magnification. (C,D) OVCAR3 cells were treated with control or 1–20 µM CM37 for six days, and 
numbers of live cells were assessed by quantifying ATP production by using the Cell-Titer Glo assay. 
Spheres were photographed with an inverted microscope at 100× magnification. (E–H) Relative 
expression of ALDH1A isoforms in OVCAR3, SKOV3, OVCAR5, and COV362 cells grown as spheres 
as measured by qRT-PCR. Bars represent averages of triplicate measurements; ** corresponds to p < 
0.01; **** corresponds to p < 0.0001. 
2.2. Characterization of ALDH1A1-Depleted Ovarian Cancer Cells 
To determine the functional role of ALDH1A1 in the maintenance of stem cell-like 
characteristics, we knocked-down ALDH1A1 in OC cell lines. Lentiviral-mediated ALDH1A1 
Figure 2. Effects of CM37 on OC sphere formation: CM37 disrupts ALDH1A1-mediated sphere
formation and growth under low attachment conditions. (A,B) OVCAR8 cells were treated with
DMSO or 1–20 µM CM37 for six days, and numbers of live cells were assessed by quantifying
ATP production via Cell-Titer Glo assay. Spheres were photographed with an inverted microscope
at 100× magnification. (C,D) OVCAR3 cells were treated with control or 1–20 µM CM37 for six days,
and numbers of live cells were assessed by quantifying ATP production by using the Cell-Titer Glo
assay. Spheres were photographed with an inverted microscope at 100× magnification. (E–H) Relative
expression of ALDH1A isoforms in OVCAR3, SKOV3, OVCAR5, and COV362 cells grown as spheres
as measured by qRT-PCR. Bars represent averages of triplicate measurements; ** corresponds to p < 0.01;
**** corresponds to p < 0.0001.
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2.2. Characterization of ALDH1A1-Depleted Ovarian Cancer Cells
To determine the functional role of ALDH1A1 in the maintenance of stem cell-like characteristics,
we knocked-down ALDH1A1 in OC cell lines. Lentiviral-mediated ALDH1A1 depletion resulted in
a 4.5-fold reduction in ALDH1A1 mRNA expression levels in OVCAR3 cells (Figure 3A). ALDH1A1
down-regulation reduced the number of spheres and attenuated ATP production corresponding to
numbers of live cells in OVCAR3 spheroids (Figure 3B–D). Likewise, targeted depletion of ALDH1A1
in OVCAR5 cells resulted in a 2.5-fold decrease in mRNA expression levels (Figure 3E), which led to
reduced numbers of spheres and ATP production corresponding to numbers of cells proliferating in
spheres (Figure 3F–H).
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Figure 3. Effects of ALDH1A1 knock down on stemness phenotype. (A) OVCAR3 cells were 
transfected with nontargeting shRNA (Sh-Control) or shRNA targeting ALDH1A1 (sh-ALDH1A1), 
and ALDH1A1 knockdown was verified by qRT-PCR. (B,D) Sphere formation in OVCAR3 cells stably 
transfected with sh-Control and sh-ALDH1A1 and plated under low attachment conditions for six 
days. Spheres were photographed (100× magnification, B); numbers of live cells were assessed by 
using the Cell-Titer Glo assay (C), and the numbers of sphere per well were counted (D). (E) OVCAR5 
cells were transfected with sh-Control or sh-ALDH1A1 and assessed for ALDH1A1 knockdown by 
qRT-PCR analysis. (F–H) OVCAR5 cells were plated under low attachment conditions for six days; 
spheres were photographed (100× magnification, F); numbers of live cells were assessed by using the 
Cell-Titer Glo assay (G), and the numbers of sphere per well were counted (H). Bars represent 
averages of triplicate measurements; *** corresponds to p < 0.001; ** corresponds to p < 0.01; * 
corresponds to p < 0.05. (I) Percentage of ALDH+ cells in sh-Control or sh-ALDH1A1 transfected 
OVCAR3 cells. (J) OVCAR3 sh-Control and sh-ALDH1A1 were subcutaneously injected into the 
flanks of nude mice and tumor initiation was assessed; data captures the total number of tumors 
detectable at week #3 and at week #4. (K) Time to tumor initiation measured in days after 
subcutaneous injection of sh-Control and sh-ALDH1A1 transfected cells in the flanks of nude mice (n 
= 6 per group). 
3. Effects of ALDH1A1 knock down n stemness phenotype. (A) OVCAR3 cells were tran fected
with nontargeting shRNA (Sh-Control) or shRNA targeting ALDH1A1 (sh- ), and ALDH1A1
k ockdown was verified by qRT-PCR. (B,D) Sphere formation in OVCAR3 cells stably transfected with
sh-Control and sh-ALDH1A1 and plated under low att chme t conditions for six days. Spheres were
photograph d (100× magnification, B); nu bers of live cells were assessed by using the Cell-Tit r Glo
assay (C), and the numbers of sphere per well were counted (D). (E) OVCAR5 cells were transfected
with sh-Control or sh-ALDH1A1 and assessed for ALDH1A1 knockdown by qRT-PCR analysis.
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(F–H) OVCAR5 cells were plated under low attachment conditions for six days; spheres were
photographed (100× magnification, F); numbers of live cells were assessed by using the Cell-Titer
Glo assay (G), and the numbers of sphere per well were counted (H). Bars represent averages of
triplicate measurements; *** corresponds to p < 0.001; ** corresponds to p < 0.01; * corresponds to
p < 0.05. (I) Percentage of ALDH+ cells in sh-Control or sh-ALDH1A1 transfected OVCAR3 cells.
(J) OVCAR3 sh-Control and sh-ALDH1A1 were subcutaneously injected into the flanks of nude mice
and tumor initiation was assessed; data captures the total number of tumors detectable at week
#3 and at week #4. (K) Time to tumor initiation measured in days after subcutaneous injection of
sh-Control and sh-ALDH1A1 transfected cells in the flanks of nude mice (n = 6 per group).
Flow cytometry assessed ALDH activity in OVCAR3 cells stably transduced with sh-control
and sh-ALDH1A1; 11% of sh-control cells exhibited high ALDH activity while 6.3% of sh-ALDH1A1
cells exhibited high ALDH activity, consistent with a reduction in enzyme levels, and perhaps in
stemness characteristics (Figure 3I). Of note, ALDH1A1 depletion in OVCAR3 cells was associated with
2.3-fold increase in ALDH1A3 mRNA levels (Supplementary Figure S1A), while OVCAR5 sh-ALDH1A1
cells showed a 2.6- and 1.8-fold increase in ALDH1A3 and ALDH3, respectively (Supplementary Figure
S1B). These data suggest that significant compensation may exist between ALDH isoforms to maintain
the necessary pool of cellular aldehyde dehydrogenase activity.
To further evaluate the significance of ALDH1A1 to cancer stemness, we sought to assess
the effects of ALDH1A1 knock down to the tumor initiation capacity (TIC) of OC cells. For this,
20,000 OVCAR3 sh-control or sh-ALDH1A1 cancer cells were injected in the flanks of immune
compromised female nude mice. At three weeks, five of the six mice injected with sh-control cells
developed detectable tumors (e.g., visible tumors >2 mm in greatest dimension), while none of
the mice injected with sh-ALDH1A1 developed tumors. At four weeks, all of the mice injected with
sh-control cells had detectable tumors, however only 50% of mice injected with sh-ALDH1A1 OVCAR3
cells developed tumors >2 mm (Figure 3J). The median time to tumor initiation defined as the time
between tumor cell inoculation and formation of detectable tumors was 27 days for sh-control cells
and 33 days for sh-ALDH1A1 OVCAR3 cells (p = 0.003; Figure 3K), suggesting that this isoform
plays a functional role in OC cell tumorigenicity. Although tumor initiation from sh-ALDH1A1
transfected cells was delayed compared to control cells, there was no significant difference in tumor
size at the final endpoint.
The effects of ALDH1A1 downregulation were further studied in other OC cells transiently
transfected with ALDH1A1-targeting siRNAs. Transient transfection of siRNAs sequences targeting
ALDH1A1 mediated effective down regulation of the enzyme in COV362 and OVCAR 5 cells
(Figure 4A,D). ALDH1A1 knockdown significantly reduced spheroid formation under low attachment
conditions in COV362 (Figure 4B,C) and in OVCAR5 cells (Figure 4D–F), as measured by microscopy
and sphere counting, supporting the significance of this enzyme to spheroid proliferation.
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Figure 4. Effects of ALDH1A1 depletion on sphere for ation. (A) COV362 cells were transfected with
50 n scrambled siRNA (si-Control) or siRNA targeting ALDH1A1 (si-ALDH1A1 sequences #6 and #9);
ALDH1A1 knockdown was assessed by qRT-PCR. (B) COV362 were plated under low attachment
conditions for six days; spheres were photographed under 100× magnification. (C) The numbers of
spheres per well were counted (five fields per well); graph depicts fold-change. (D) OVCAR5 cells
were transfected with 50 nM si-Control or si-ALDH1A1 siRNA; cells were assessed for ALDH1A1
knockdown by qRT-PCR analysis. (E) OVCAR5 cells were plated under low attachment conditions for
six days; spheres were photographed under 100× magnification. (F) The number of spheres per well
were counted (five fields per well); graph depicts fold-change between cells transfected with control
and ALDH-targeting siRNA. Bars represent averages of triplicate measurements; *** corresponds to
p < 0.001; ** corresponds to p < 0.01; * corresponds to p < 0.05.
2.3. CM37 Causes Increased DNA Damage in OC Cells
Several members of the aldehyde dehydrogenase family have been associated with cellular
processes that minimize the impact of reactive oxygen species (ROS), which in turn are involved in
oxidative stress-induced DNA damage. To elucidate the potential mechanism by which ALDH1A1
inhibition blocks cancer cell proliferation as spheres, we assessed whether CM37 induced DNA
damage. CM37-treated OVCAR5 and SKOV3 exhibited increased DNA damage, as evidenced
by robust induction of γH2AX, measured through immunofluorescence (IF) staining (Figure 5A).
Consistent with these data, western blot analysis confirmed CM37-mediated induction of γH2AX
in OC cells. The inhibitor caused robust γH2AX induction within 45 minutes in OV90, OVCAR5,
and OVCAR3 cells grown as spheres (Figure 5B,C). To further analyze DNA damage response induced
by this inhibitor, ALDH+ FACS-sorted OVCAR3 cells were treated with 1 µM CM37 for 6 h, and a DNA
damage-focused RT2 PCR array was used to measure mRNA transcript levels of a panel of known
genes related to DNA damage response and repair (Figure 5D). Among the genes included on this
array, CM37 induced a 2.98-, 10.8-, and 8.01-fold increase in the mRNA transcripts of NEIL3, RAD3,
and RAD21A, respectively (Figure 5E). QRT-PCR analysis of ALDH+ FACS-sorted OVCAR3 cells
treated with 1 µM CM37 confirmed a 2-fold (p = 0.02) increase in NEIL3 mRNA levels, although RAD21
and RAD23A mRNA levels were not significantly changed (Figure 5F). However, no significant
change in NEIL3, RAD23, or RAD21A mRNA expression levels was observed in ALDH+ FACS-sorted
OVCAR5 cells treated with 1 µM CM37 (Figure 5G). Other DNA damage response genes (RAD9A
and RAD9B, but not RAD51) were upregulated in response to treatment with CM37 in OVCAR5
cells grown as spheroids (Figure 5H). We then sought to determine whether ALDH1A1 knockdown
in OVCAR3 and OVCAR5 cells recapitulated the effects of CM37 on NEIL3, RAD21, and RAD23A
mRNA expression levels. ALDH1A1 depletion in OVCAR3 cells resulted in a 2.65-fold (p < 0.0001)
and 1.95-fold (p < 0.0001) induction in the expression of NEIL3 and RAD21, however RAD23A mRNA
expression levels were not changed. Conversely, ALDH1A1 depletion in OVCAR5 cells resulted in
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a 2.6-fold (p = 0.003) upregulation in NEIL3 mRNA levels, but RAD21 and RAD23A mRNA levels
were not significantly changed (Figure 5I,J). Collectively, these data suggest that the novel ALDH1A1
inhibitor CM37 and ALDH1A1 knockdown induced modest to moderate DNA damage response in
OC spheroids.
2.4. CM37 Induces ROS in Ovarian Cancer Cell Lines
Knowing that ALDH participates in the regulation of the intracellular redox, and considering
that reactive oxygen species (ROS) are inducers of DNA damage, we evaluated the effects of
CM37 on intracellular ROS levels in OC cell lines. OC cell suspensions were treated with 1 µM
CM37 or DSMO for 60 minutes before measurement of intracellular ROS through flow cytometry.
CM37 treatment resulted in elevated ROS production in OVCAR5 cancer cells, although the increase
did not reach statistical significance (p = 0.06) (Figure 6A,B). However, treatment with 1 µM CM37
resulted into a significant 1.2-fold (p = 0.005), and 1.74-fold (p = 0.02) ROS elevation in OVCAR3
and SKOV3 cell suspensions, respectively (Figure 6C,D). These data led us to hypothesize that
by blocking ALDH1A1, CM37 treatment increases intracellular ROS levels, which in turn cause
DNA damage, hindering cell survival and proliferation. To evaluate this possibility, we evaluated
spheroid formation in OVCAR5 cells treated with CM37 in the presence or absence of Trolox
(6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid), a ROS scavenger. Spheroid formation
was significantly reduced in OVCAR5 cells treated with 100 nM CM37 (p = 0.017) and this effect
was reversed in cells pre-treated with 50 µM trolox (p = 0.05) (Figure 6E,F). Furthermore, the mild
induction of γH2AX caused by treatment with CM37 and measured by western blotting in OVCAR5
and OVCAR3 cells was attenuated by pre-treatment of the cells with 20 µM Trolox for 1 h (Figure 6G,H).
Collectively, these data support the concept that CM37 is involved in the regulation of intracellular
oxidative stress.
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Figure 5. CM37-induced DNA damage response in ovarian cancer cell lines. (A) Immunofluorescent
staining illustrates increased γH2AX abundance in OVCAR5 and SKOV3 cells cultured as spheres
and treated with 100 nM CM37 for 72 h; 60× magnification. (B,C) Western blot demonstrating
increased γH2AX protein levels in OC cell lines cultured as spheres and treated with CM37 for 45 min.
(D,E) OVCAR3 ALDH+ cells were treated with 1 µM CM37 for 6 h prior to measurement of genes
implicated in DNA damage response. (F,G) qRT-PCR measured expression of NEIL3, RAD21, RAD23
mRNA expression levels in ALDH+ OVCAR3 and OVCAR5 cells treated with 1 µM CM37. (H) qRT-PCR
measured expression of RAD9A, RAD9B, RAD51 mRNA expression levels in OVCAR5 cells treated
with 10 µM CM37. (I,J) QRT-PCR measured mRNA expression levels of NEIL3, RAD21, and RAD23 in
OVCAR3 and OVCAR5 cells stably transduced with sh-Control or sh-ALDH1A1 lentiviral particles.
Bars represent averages of triplicate measurements; *** corresponds to p < 0.001; ** corresponds to
p < 0.01; * corresponds to p < 0.05.
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Figure 6. C 37 increases reactive oxygen species (ROS) levels in OC cells. (A) Representative flow
cytometry for total intracellular ROS levels in OVCAR5 cells treated with DMSO or 1 µ CM37.
(B–D) Fold change in ROS levels measured by flow cytometry in SKOV3, OVCAR3, and OVCAR5
treated with DSMO or 1 µM CM37 for 1 h. (E,F) Sphere formation in OVCAR5 cancer cells treated
with 100 nM CM37 +/− 50 µM trolox for three days. Spheres were photographed under an inverted
microscope (E) and counted (five fields per well; (F). Bars represent averages of triplicate measurements;
* corresponds to p < 0.05. (G,H) Western blot measures γH2AX, H2AX, and β-actin protein levels in
OVCAR5 and OVCAR3 cells cultured as spheres for six days and treated with 5 µM CM37 for 45 min,
after 1 h or not of pre-treatment with Trolox (20 µM).
3. Discussion
Our data provide proof of principle support for the concept that ALDH inhibitors block
stemness and cell proliferation in OC models, and back further development of such small molecules
for targeting and eradicating CSCs. We show that CM37, a selective and potent ALDH1A1
inhibitor [25], effectively inhibits OC cell proliferation as spheres, induces accumulation of intracellular
ROS, and inflicts DNA damage. These effects were consistent between cell lines and primary
cancer cells sorted from malignant ascites. Similar effects were observed following knockdown
of the ALDH1A1 isoform, supporting its significance to the maintenance of stemness characteristics.
However, functional redundancy among isoforms in this family and the distinct patterns of expression
of isoforms in various models or cell lines may limit the activity of highly selective inhibitors,
suggesting that drugs with a broader spectrum of inhibitory activity might induce more potent
anti-CSCs results. Our findings have several implications.
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Aldefluor activity has been increasingly recognized as a marker of cells with progenitor/stemness
characteristics in OC [22], but also in other cancer models [13,24]. There are 19 genes encoding
various aldehyde dehydrogenases with similar functions and tissue specific patterns of expression.
The main catalytic activity of ALDHs is to oxidize aldehydes generated from cellular metabolism
through an NAPD(P)-dependent reaction. However, ALDHs participate in other cellular processes,
including the regulation of retinoid signaling by conversion of retinal into retinoic acid. This role
places a spotlight on ALDH as a key regulatory node in the process of cellular differentiation. Indeed,
ALDH inhibition by DEAB was shown to delay cytokine-induced differentiation of hematopoietic
progenitor cells through direct inhibition of retinoic signaling in these progenitors [27].
ALDH1A enzymes are expressed abundantly in the liver, pancreas, intestine, and hypophysis
and are present variably in cancer, particularly in colon, liver, pancreatic, and some ovarian and breast
tumors [17]. Among the various isoforms, ALDH1A1, 1A2, and 1A3 have been shown to be expressed
and active in cancer [28] and have been implicated in the development of chemo-resistance [17,25],
a key characteristic of CSCs. Evaluation of specific isoforms in cancer tissue is somewhat limited
by the specificity of available antibodies. Additionally, ALDH expression is considered to be
restricted to progenitor cells, a rare cell population within tumors, further limiting the ability
to distinguish between isoforms. The available literature supports that ALDH1A3, ALDH3A2,
and ALDH7A1 isozymes are expressed more abundantly in ovarian tumors, particularly in mucinous
and endometrioid type tumors [16]. Our current results support the significance of ALHDH1A1
isoform to proliferation of OC cells as spheres and maintenance of a CSC phenotype, but also show
that other ALDH1A isoforms are expressed in OC cells and could compensate for selective inhibition
or knock down of ALDH1A1.
ALDH1 activity is increased in OC cells growing as spheroids compared to monolayers [18,25]
and in OC cells and tumors that survived exposure to platinum [18,19]. Recent data from our
group and others demonstrate that platinum activates cancer-associated fibroblasts in ovarian
xenografts, thereby stimulating IL6 secretion, which in turn, transcriptionally upregulates ALDH
activity [19]. These observations suggest that a potential application of ALDH inhibitors could
occur after completion of standard platinum-based therapy, with the goal of eradicating residual,
chemotherapy-resistant, or tolerant cells, which are enriched for ALDH activity and responsible
for giving rise to recurrent, recalcitrant tumors. Other strategies which could indirectly block
ALDH1A1 include agents targeting transcriptional regulatory mechanisms, such as bromodomain
and extra terminal (BET) inhibitors [29], DNA hypomethylating agents [18], and STAT inhibitors [19]
which have been shown to eliminate ALDH+ cells residual after platinum treatment. Interestingly,
ALDH1A expression was shown to be inducible by BRD4 and by STAT3 at transcriptional level,
however, agents targeting these circuitries may have other non-specific effects and could affect stemness
phenotype through non-ALDH related mechanisms.
Here, we tested CM37, a first in class small molecule, discovered as the lead compound from
a high-throughput screen of the ChemDiv library. While the compound was found to be potent
at nanomolar concentrations in vitro and highly selective for ALDH1A1, its limited bioavailability
and short half-life in vivo (~2 minutes) lessened its activity in vivo. Importantly, the inhibitor was
tolerated in vivo at concentrations up to 20 mg/kg, without significant systemic toxicity. Efforts to
improve its properties are ongoing by using rational chemistry design strategies specifically targeting
the “arms” that extend from the central scaffold in order to improve the metabolic stability and modify
the lipophilicity of the compound. The observed spectrum of activity of CM37 is in line with reports
testing other inhibitors in this class. For example, disulfiram, a broad ALDH inhibitor, was shown to
eradicate paclitaxel-resistant triple negative breast cancer cells [24] as well as kinase inhibitor-tolerant
lung cancer cells addicted to specific mutant oncogene drivers [30]. However, disulfiram is non-specific
and has high systemic toxicity, limiting its potential clinical applicability. Therefore, development
of more selective inhibitors has garnered interest. A quinoline-based series of analogues which
block ALDH1A1 has been recently described. The lead compound had activity similar to CM37
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in OC spheroids and promoted synergy with paclitaxel [31]. Optimization of other novel chemical
structures inhibiting ALDH1A1, A2, and A3 has been reported [32]. The lead compound was shown to
deplete CSCs, synergize with platinum, and have in vivo activity when injected intra-tumorally [32].
These emerging results point to growing interest exploring this pathway, which is clearly significant to
the survival of drug-resistant cancer cells.
The mechanism by which ALDH inhibitors target CSCs remains not fully understood. Here we
show that CM37 induces accumulation of ROS, which in turn, causes DNA damage. A disturbance in
the intracellular redox balance was also shown to be induced by disulfiram in drug-tolerant lung cancer
cells [30] and is consistent with the known functions of the target enzyme. Knockdown of ALDH1A1
by siRNA was shown to induce DNA damage in another report, consistent with our findings [22].
Thus, we predict that sensitivity to ALDH inhibitors is likely be influenced by the selective expression
of ALDH isoforms active in specific contexts and/or by the presence of other mechanisms that
regulate oxidative stress in parallel. We cannot exclude that CM37 and other ALDH inhibitors may
block stemness through other pathways (e.g., differentiation pathways). Collectively, our results
consolidate the concept that ALDH1A1 plays an important role regulating stemness in ovarian cancer,
describe the activity of a novel inhibitor targeting this rare and resistant cell population, and support
continued efforts to optimize this new class of anti-cancer agents.
4. Materials and Methods
4.1. Chemicals and Reagents
CM37 was synthesized in the Chemical Genomics Medicinal Chemistry Core at Indiana
University School of Medicine, Indianapolis. Trolox was purchased from Sigma-Aldrich
(St. Louis, MO, USA). The ALDEFLUOR ALDH activity assay kit was purchased from StemCell
Technologies (Vancouver, BC, Canada). Antibodies against phospho-histone H2AX (mAB #9718)
and histone H2AX (2595S) were purchased from Cell Signaling Technology (Danvers, MA, USA),
and against GAPDH from Biodesign International (Saco, ME, USA). The secondary HRP-conjugated
antibodies were purchased from Amersham Biosciences (San Francisco, CA, USA) and Santa Cruz
Biotechnology Inc. (Santa Cruz, CA, USA). siRNAs targeting the ALDH1A1 isoform and non-targeting
control siRNA were purchased from Dharmacon (Lafayette, CO, USA). Lentiviral particles encoding
shALDH1A1 or scrambled, non-silencing control (Sh-control) siRNA were obtained from Sigma-Aldrich.
4.2. Cell Lines
The human OC cell lines COV362 and OVCAR5 were provided by Dr. Kenneth Nephew,
(Indiana University). SKOV3, OVCAR3, and OV90 OC cell lines were purchased from American
Type Culture Collection (Rockville, MD, USA). Cell lines were authenticated using Short Tandem
Repeat (STR) DNA profiling analysis and tested mycoplasma negative (IDEXX Bioresearch,
Columbia, MO, USA). SKOV3 and primary cells recovered from tumors or ascites were cultured
in 1:1 MCDB 105 and M199 (Cellgro, Manassas, VA, USA) supplemented with 10% FBS (Cellgro)
and 100 units/mL penicillin and 100 µg/mL streptomycin. OVCAR3 were cultured in DMEM
high glucose medium supplemented with 10% FBS and 100 units/mL penicillin and 100 µg/mL
streptomycin. OVCAR5 cells were grown in DMEM (high glucose), 10% (FBS), 0.1 mM non-essential
amino acids (NEAA), 2 mM L-glutamine, and antibiotics. Spheroid cultures were maintained in
Mammocult Complete medium (StemCell Technologies) and ultra-low attachment plates. Cells were
cultured at 37 ◦C in a humidified incubator with 5% CO2 supply.
4.3. Patient-Derived Primary Human OC Cells
De-identified malignant ascites fluid was obtained from subjects with high-grade serous
OC or with primary peritoneal carcinomatosis. The samples were obtained at the Indiana
University Simon Cancer Center (IUSCC) and Northwestern University Robert H. Lurie Cancer
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Center under IRB approved protocols (Indiana University CRO#505; Northwestern University
#STU00202468, respectively). For primary cell isolation from human specimens, we used previously
described methods [21]. In brief, freshly collected ascites specimens were centrifuged at low
speed for 20 minutes. After removal of the fluid, cell pellets were dispersed mechanically
and dissociated by using Cellstripper (Corning, Corning, NY, USA; Cat# 25-056-CI). Red blood cell
(RBC) (BioLegend, San Diego, CA; Cat#420301) lysis buffer was used to remove RBC and DNase
(Qiagen, Valencia, CA, USA; Cat# 79254) was used to digest free DNA in cell suspensions.
The single cell suspensions were filtered through a 40 µm cell strainer (ThermoFisher Scientific,
Waltham, MA, USA; Cat#NC0147038) to remove other debris before plating in non-adherent plates.
4.4. In Vivo Xenograft Studies
Foxn1nu nude mice were purchased from Harlan (Indianapolis, IN, USA), and were maintained
at the Northwestern University Center for Comparative Medicine in accordance with the National
Institutes of Health guidelines and following protocols approved by the Northwestern University
Animal Use and Care Committee (Protocol #IS00003060). In brief, 20,000 OVCAR3 OC cells stably
transfected with sh-control or sh-ALDH1A1 lentivirus were subcutaneously injected into the flanks
of 6–8-week-old female nude mice. Tumors were assessed and measured twice weekly to assess tumor
initiation. Time to tumor initiation was determined as the time from inoculation to the time when
tumors were detectable by palpation (measuring at least 2 mm in greatest dimension). Tumors were
allowed to form and grow until they reached 1500 mm3. At that point, mice were euthanized
and tumors were harvested, measured, and weighed.
4.5. Sphere Formation Assay
The sphere formation assay was performed as previously described, with some modifications [21,
25]. Briefly, OC or primary cells were seeded at a density of 104/100 µL in complete MammoCult
media supplemented with 1.5% penicillin/streptomycin (Stemcell Technologies, Cambridge, MA, USA)
in ultra-low attachment plates (Corning, Corning, NY, USA) and allowed to form spheroids for 7 days.
Images were captured, and the numbers of spheres/well were quantified. The data are presented
as means ± SEM of triplicate, independent experiments.
4.6. ALDEFLUOR Assay and Fluorescence-Activated Cell Sorting
ALDH1 enzymatic activity was measured using the Aldefluor assay kit, per manufacturer
recommendations (Stemcell Technologies). Briefly, OC monolayers were dissociated with trypsin
and resuspended in Aldefluor assay buffer at a density of 2 × 106 cells/mL. The cell suspension
was treated with 5 µL/mL bodipyaminoacetaldehyde (BAAA) and incubated in a 37 ◦C water bath
for 60 minutes. The control sample (ALDH-negative cells), was derived from a 500 µL aliquot
of BAAA-treated cell suspension incubated with a 15–30 µM of the ALDH inhibitor, diethylamino
benzaldehyde (DEAB), and incubated as mentioned above. As such, the ALDH1A1-positive population
was identified and gated using DEAB-treated cells as our control sample. The relative increase in FITC
signal of the ALDH-positive cells was determined by a FACS Aria II flow cytometer (BD Biosciences,
San Jose, CA, USA) and analyzed in at least two to three independent experiments.
4.7. CCK-8 Colorimetric Assay
The numbers of live cells were assessed by using the CCK-8 assay and following
the manufacturer’s specifications (Dojindo Molecular Technologies, Rockville, MD, USA).
Briefly, OC cells were seeded at a density of 104/100 µL in complete MammoCult media supplemented
with penicillin/streptomycin (Stemcell Technologies, Cambridge, MA, USA) in 96-well ultra-low
attachment plates (Corning, Corning, NY, USA). Numbers of live cells were assessed after 7 days by
adding 10 µL of CCK-8 reagent to each well. Absorbance at 450 nm was quantified using a BioTek plate
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reader (Winooski, VT, USA). Assays were performed in at least four replicates. Data are presented
as means ± SEM.
4.8. Cell Titer-Glo Cell Viability Assay
Spheroids were cultured as mentioned above. Numbers of live cells was measured by using
Cell Titer-Glo kit (Promega, Madison, WI, USA) per the manufacturer’s recommendations with
some modifications. Briefly, an equal volume of CellTiter- Glo reagent was added to each well
and the plate was covered with aluminum foil and incubated on an orbital shaker for 30 min at RT.
Lysates were transferred to opaque, low-binding polystyrene microplates (Corning, Corning, NY, USA)
and allowed to equilibrate for 10 min. ATP abundance was quantified in a SpectraMax GeminiXS
luminescence/fluorescence plate reader (Molecular Devices, Palo Alto, CA, USA). Experiments were
performed in quadruplicate and repeated at least twice. Data are presented as means ± SEM.
4.9. Quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR)
Total RNA was extracted using RNA STAT-60 Reagent (Tel-Test Inc., Friendswood, TX, USA)
and reverse-transcribed using an iScript cDNA kit (Bio-Rad, Hercules, CA, USA). Real-time
PCR was used to measure ALDH, NANOG, OCT4, SOX2, NIEL3, RAD2, RAD9A, RAD9B,
RAD51, and RAD23A expression, and human glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
or beta-actin (ACTB/β-actin) were used as references. The relative expression of target genes was
calculated using the ∆∆Ct method. Results are presented as the means ± SD of at least triplicate
experiments. Primers are listed below (Table 1).
Table 1. Real-time PCR Primers.











RAD 51 GAGACCGAGCCCTAAGGAGA TTAGCTCCTTCTTTGGCGCA
RAD9B GCCTGCTTTTTAGGGCGGAT ACAATGGCATCAGCAAGCAA
4.10. DNA Damage Pathway PCR-Array
The human DNA Damage Pathway RT2 Profiler PCR Array and RT2 Real-Timer SyBR Green/ROX
PCR Mix were purchased from Qiagen (Valencia, CA, USA). PCR was performed on an ABI Prism 7900
Sequence Detector (Applied Biosystems, Waltham, MA, USA). Data analysis was performed based
on the ∆∆Ct method with normalization of the raw data to the housekeeping genes, included in
the array, using a Microsoft Excel algorithm provided by the manufacturer. For each gene, fold-changes
were calculated as the difference in gene expression between control and CM37-treated spheroid
cultures. An ontology classification assignment for each gene was performed, and fold-changes were
calculated and expressed as percent of composition for each represented pathway in control versus
treated spheres.
4.11. ALDH Enzymatic Activity
Inhibitory activity of CM37 against ALDH orthologs was tested by using purified recombinant
human ALDH1A1, ALDH1A2, ALDH1A3, ALDH2, and ALDH3A1. Dehydrogenase activity of
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ALDH1A1, ALDH1A2, ALDH1A3, and ALDH2 were measured in a solution containing 100–200 nM
enzyme, 200 µM NAD+, 1% DMSO, and 100 µM propionaldehyde in 50 mM sodium BES, pH 7.5.
ALDH3A1 activity was measured using 25 nM enzyme, 200 µM NAD+, 1% DMSO, and 1 mM
benzaldehyde in 100 mM sodium phosphate buffer, pH 7.5. All assays were performed at 25 ◦C
and were initiated by the addition of the aldehyde substrate following pre-incubation with compound
and NAD+. The values represent the average of three independent experiments. Data are presented
as percent inhibition.
4.12. Immunofluorescence (IF)
OVCAR5 and SKOV3 OC cells were seeded at a density of 5 × 104/mL in complete MammoCult
media supplemented with penicillin/streptomycin (Stemcell Technologies, Cambridge, MA, USA)
in 6-well ultra-low attachment plates (Corning, Corning, NY, USA) for 5 days and treated with
CM37 (1 µM) or DSMO every other day. OC spheroids were fixed, permeabilized, and stained
with γH2AX antibody (1:200, Cell Signaling Technology, Danvers, MA, USA). Spheroids were
counterstained with Alexa fluor-488 anti-rabbit secondary antibody (1:1000; Molecular Probes, Eugene,
OR, USA), and nuclei were visualized by Hoechst staining (Molecular Probes). Images were captured
using a Nikon A1 Confocal Laser Microscope at the Northwestern University Center for Advanced
Microscopy (Chicago, IL, USA).
4.13. Western Blot
Cells were lysed in buffer containing leupeptin (1 µg/mL), aprotinin (1 µg/mL),
phenylmethylsulfonyl fluoride (PMSF; 400 µM), and sodium orthovanadate (Na3VO4; 1 mM).
Lysates were briefly sonicated, then cleared by centrifugation (8000× g, 10 min, 4 ◦C), and total protein
was measured using the Pierce BCA protein assay kit (ThermoFisher Scientific, Waltham, MA, USA).
The lysates were resolved by SDS-PAGE (10% Tris-HCl polyacrylamide gels, Biorad, Hercules, CA, USA)
and transferred to PVDF membranes (GE Healthcare Life Sciences, Pittsburg, PA, USA). The membranes
were rinsed in Tris-buffered saline with 0.1% Tween 20 (TBS-T) and blocked for 30 min in TBS-T
with 5% bovine serum albumin (BSA). Membranes were incubated with primary antibody overnight
at 4 ◦C, and then with secondary antibody for 1 h. Antigen–antibody complexes were visualized using
the enhanced chemiluminescence kit (Thermo Scientific, Waltham, MA, USA), and images were obtained
using the ImageQuant LAS 4000 mini-imager (GE Healthcare, Pittsburgh, PA, USA). Images were
quantified by densitometry using ImageJ32 software (National Institutes of Health, Bethesda, MD, USA).
All values were corrected for the integrated optical density (iOD) and normalized to loading controls.
4.14. ROS Activity Assay
Mean reactive oxygen species (ROS) accumulation was measured by the DCFDA/H2DCFDA-Cellular
Reactive Oxygen Species Detection Assay Kit (Abcam, Cambridge, MA, USA). Briefly, OC cells were
resuspended at a concentration of 104 cells/mL in complete MammoCult media supplemented with
penicillin/streptomycin (Stemcell Technologies, Cambridge, MA, USA) in 6-well ultra-low attachment
plates (Corning, Corning, NY, USA) and allowed to form spheroids for 48 h. Spheroids were dissociated
using trypsin, rinsed with complete media (DMEM + 10FBS, + Pen/Strep), then resuspended in complete
MammoCult media supplemented with penicillin/streptomycin. Cell suspensions were treated with 20µM
DCFDA and incubated at 37 ◦C for 30 minutes, then treated with the indicated doses of CM37 or DSMO
for 30 min–1 h, depending on the cell line. Positive control samples were treated with 100 µM TBHP. 1 µM
propidium iodide was added for cell death exclusion immediately preceding mean ROS measurement by
flow cytometry. Data are presented as means± SEM of independent, triplicate experiments.
5. Conclusions
Here we describe the activity of CM37, a new specific and potent small molecule inhibitor for
ALDH1A1 in ovarian cancer models enriched in cells with stemness characteristics. Together with
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siRNA-mediated knockdown of the enzyme, the results obtained using CM37 provide proof of principle
supporting the role of ALDH1 in cancer stemness. Our data demonstrate that by fine tuning the levels of
intracellular oxidative stress, ALDH1A1, protects cancer cells from DNA damage, enhancing spheroid
proliferation and tumorigenicity.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/4/502/s1,
Figure S1: ALDH1A3 expression in cells transfected with sh-RNA targeting ALDH1A1 or scrambled shRNA.
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